Drug Profile
TRP 002
Alternative Names: TRP-002Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Turing Pharmaceuticals
- Developer Vyera Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Developmental disabilities
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Developmental disabilities in USA (unspecified route)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Developmental-disabilities in USA
- 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals